ストックスクリーナーアプリを入手
12.21
2.35%
0.28
アフターアワーズ：
12.21
Urogen Pharma Ltd (URGN) 最新ニュース
URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference - StockTitan
(URGN) Investment Analysis - Stock Traders Daily
Rice Hall James & Associates LLC Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen Pharma (URGN) to Release Quarterly Earnings on Wednesday - MarketBeat
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - BioSpace
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - StockTitan
(URGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
UroGen started at buy by EF Hutton, RTGel technology cited - MSN
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years - Yahoo Finance
FDA accepts UroGen's NDA for bladder cancer treatment - Investing.com India
When Would Be The Best Time To Buy UroGen Pharma Ltd (NASDAQ: URGN) Stock? - Stocks Register
URGN’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
UroGen Pharma maintains Outperform stock rating on new drug application - Investing.com
UroGen Pharma Ltd (URGN) looking to reclaim success with recent performance - SETE News
UroGen Pharma maintains Outperform stock rating on new drug application By Investing.com - Investing.com UK
UroGen Pharma (NASDAQ:URGN) Receives "Outperform" Rating from Oppenheimer - MarketBeat
Wesbanco Bank Inc. Buys Shares of 74,400 UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment - Pharmaceutical Technology
UroGen Pharma Says FDA Accepts NDA for UGN-102 - Marketscreener.com
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - The Bakersfield Californian
UroGen Pharma Ltd (URGN) is a good investment, but the stock may be undervalued - US Post News
UroGen Pharma's (URGN) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
UroGen Pharma (NASDAQ:URGN) Lifted to Strong-Buy at EF Hutton Acquisition Co. I - MarketBeat
EF Hutton initiates UroGen Pharma shares with Buy rating By Investing.com - Investing.com South Africa
EF Hutton Initiates Coverage of UroGen Pharma (URGN) with Buy Recommendation - MSN
UroGen Pharma Ltd [URGN] Chief Medical Officer makes an insider sale of 859 shares worth 11,236. - Knox Daily
Healthy Upside Potential: UroGen Pharma Ltd (URGN) - SETE News
UroGen Pharma announces executive changes By Investing.com - Investing.com South Africa
UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
UroGen Pharma Announces Departure of CFO and Appointment of New CFO - MarketBeat
UroGen Appoints Chris Degnan as Chief Financial Officer - citybiz
UroGen Pharma announces executive changes - Investing.com
Urogen Pharma falls on CFO appointment - XM
UroGen Pharma Announces CFO Transition and Compensation Details - TipRanks
UroGen Pharma appoints Chris Degnan as CFO - Investing.com
Marshall Wace LLP Buys Shares of 42,841 UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
News: UroGen Pharma Ltd’s Chief Medical Officer Schoenberg Mark reduceds 859 shares - Knox Daily
What technical indicators reveal about URGN stock - US Post News
Market Update: UroGen Pharma Ltd (URGN) Sees Negative Movement, Closing at 12.42 - The Dwinnex
Millennium Management LLC Purchases 1,119,019 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen Pharma (STU:UR8) 9-Day RSI : 49.01 (As of Nov. 03, 2024) - GuruFocus.com
UroGen begins subject dosing in Phase III bladder cancer drug trial - Clinical Trials Arena
UroGen Pharma retains Buy rating from H.C. Wainwright By Investing.com - Investing.com Australia
UroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at HC Wainwright - MarketBeat
URGN (UroGen Pharma Ltd) may reap gains as insiders became active recently - Knox Daily
Stock Surge: UroGen Pharma Ltd (URGN) Closes at 12.48, Marking a -1.73 Increase/Decrease - The Dwinnex
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Business Wire
Is the UroGen Pharma Ltd (NASDAQ:URGN) stock an investment opportunity? - US Post News
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Acquired by Point72 Asset Management L.P. - MarketBeat
UroGen Pharma secures $25M loan, eyes FDA drug approval By Investing.com - Investing.com Australia
UroGen Pharma secures $25M loan, eyes FDA drug approval - Investing.com
Great Point Partners LLC Increases Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now - Yahoo Finance
UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock - Yahoo Finance UK
UroGen Pharma reiterates stock target, outperform on strong FDA prospects By Investing.com - Investing.com Australia
Examining UroGen Pharma Ltd (URGN) more closely is necessary - US Post News
UroGen Pharma Ltd (URGN) gets rating Initiated from Guggenheim - Knox Daily
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):